Title:
Detection of the omicron variant virus with the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay

Authors:
James Regan1*
James P. Flynn1*
Manish C. Choudhary1,2
Rockib Uddin3
Jacob Lemieux2,3
Julie Boucau5
Roby P. Bhattacharyya2,3,4
Amy K. Barczak2,3,5
Jonathan Z. Li1,2*
Mark J. Siedner2,3*

*Authors contributed equally

Affiliations:
1Brigham and Women’s Hospital
2Harvard Medical School
3Massachusetts General Hospital
4Broad Institute
5Ragon Institute of MGH, MIT and Harvard

Conflicts of Interest:
All authors report no conflicts of interest

Corresponding Author:
Mark J. Siedner
Medical Practice Evaluation Center
Massachusetts General Hospital
Boston, MA 02114
617-726-4686
msiedner@mgh.harvard.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

The US Centers for Disease Control and Prevention recommends rapid testing for SARS-CoV-2 infection as a key element of epidemic control. The Abbott BinaxNow is in widespread use in the United States for self-testing and as part of public health screening campaigns, but has not been evaluated for use with the omicron variant of SARS-CoV-2. We recruited individuals testing positive for COVID-19 PCR at an academic medical center. Anterior nasal swabs were stored in viral transport media and evaluated by viral load quantification and whole genome sequencing. We created serial dilutions from $2.5 \times 10^3$- $2.5 \times 10^5$ viral copies/specimen for two delta and omicron specimens, respectively, and tested each with the BinaxNow assay per manufacturer instructions. Results were interpreted by three readers, blinded to the specimen variant and concentration. All omicron and delta specimens with concentrations of 100,000 copies/swab or greater were positive by the BinaxNow Assay, a concentration similar to previously reported limits of detection for this assay. Assay sensitivity diminished below that. This study demonstrates that Omicron variant SARS-CoV-2 infections are detected by the BinaxNow rapid antigen assay. Additional laboratory and clinical validation assessments are needed to better determine their limits of detection and performance in real-world settings.
Background

The US Centers for Disease Control and Prevention recommends rapid testing for SARS-CoV-2 infection as a key element of epidemic control (1). One such assay, the Abbott BinaxNow, has been recommended for in-home testing and implemented in public health screening campaigns (2–6). The diagnostic validity of the assay has been demonstrated in laboratory-based and clinical settings, with a sensitivity ranging from approximately 50-90%, depending on disease stage and degree of symptom, and a specificity >99%, compared to laboratory-based PCR assays (3,4,7,8).

Notably, test performance of chromatographic immunoassays such as the BinaxNow is dependent on specific viral antigens and may be impacted by changes in viral protein structure. In November 2021, the omicron variant of SARS-CoV-2 was first detected in Southern Africa, and quickly disseminated globally (9). The initially identified lineage of the omicron variant contains more than 50 mutations and deletions in comparison to ancestral lineages, including four mutations in the nucleocapsid gene, which is the target for the BinaxNow assay. Abbott, the manufacturer of the assay has reported in a press release that the assay is predicted to detect the omicron variant of SARS-CoV-2 infection (10). However, there are no published data on the validity of the assay with clinical specimens.

Methods

We conducted a laboratory-based validation of the BinaxNow assay with anterior nasal (AN) swab specimens from participants in a study of COVID-19 virology (11). We recruited individuals testing positive for COVID-19 PCR at an academic medical center. Positive AN swabs were stored in viral transport media and evaluated by viral load quantification and whole genome sequencing (12). We selected two omicron variant specimens and two delta variant specimens and produced serial dilutions to create swabs of 2.5x10⁵, 1.0x10⁵, 2.5x10⁴, and 2.5x10³ viral copies with each specimen. These dilutions were chosen to create concentrations both above and below previously reported limits of detection of the assay in a laboratory-based evaluation (8). To do so, we initially created viral concentrations of 5.0x10⁴, 5.0x10⁵, 2.0x10⁶, 5.0x10⁶ copies/mL in phosphate buffer saline, then immersed swabs from the BinaxNow kits into 50µL of each dilution until the material was fully absorbed, as previously described (8). An additional specimen with only phosphate-buffered saline was used as a negative control. The swabs were then tested according to the manufacturer’s instructions and results interpreted by three readers, blinded to the specimen variant and concentration, as positive, negative, or discordant (if not all three readers agreed). Study procedures were approved by the institutional review board of Mass General Brigham and participants gave consent for specimen testing for research purposes.

Results

The four specimens with concentrations of 100,000 copies/swab or greater were positive with both the delta and omicron variant specimens (Figure 1). Assay sensitivity was diminished
below that, with positive results in 1/4 omicron specimens and 1/3 of delta specimens (with the fourth delta specimen resulting in discordant reads between reviewers). All specimens with 2,500 copies/swab were interpreted as negative.

Conclusions

Omicron variant SARS-CoV-2 infections were detected in a laboratory-based assessment of the BinaxNow rapid antigen assay. This is the first report to our knowledge of this assay being formally assessed with the omicron variant. Although our study does not intend to identify a limit of detection for this assay, our results are qualitatively similar to previously published results suggesting the BinaxNow assay has a limit of detection of approximately 2.0x10⁴ - 7.0x10⁴ viral copies/swab (8). These data offer proof of concept that the BinaxNow rapid antigen assay can detect the Omicron variant SARS-CoV-2 infections. Future work should more thoroughly assess the diagnostic validity and range of detection of the assay for this novel variant, as well as its performance in clinical, public health and self-testing scenarios.
Figure 1. Results of a laboratory-based analytic validation of the BinaxNow SARS-CoV-2 rapid antigen assay across a range of concentrations with both delta and omicron variant viruses

*Discordant results indicate those in which there was not agreement between the three blinded readers of each test*
References


